Fairvalue-Calculator Fairvalue-Calculator
EN DE

GAGV (GAGV) Fair Value & Analysis

Consumer Defensive · AT · Market cap €26.1M

Price€13.00
Fair Value€12.71
Upside-2.2%
Quality95/100
Evidence: Medium Range €9.53 – €15.89

Fair value as of: Jun 26, 2026

Analysis

GAGV (GAGV) currently trades at €13.00, while our model-based Fair Value estimate is €12.71 — implying the stock looks roughly 2.2% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Gurktaler Aktiengesellschaft produces and distributes herbal spirits in Austria. The company was founded in 1897 and is based in Vienna, Austria.

Open the full interactive analysis →

Similar stocks

Ambev S.A (ABEV) -70% Anheuser-Busch InBev SA (BUDFF) -7% 1NBA (1NBA) -13% Fomento Económico Mexicano, S.A. (FEMSAUBD) +26% Heineken N.V (HINKF) -15% Constellation Brands, Inc (STZ) +24%

Frequently asked questions

Is GAGV (GAGV) undervalued?
As of Jun 26, 2026, our model estimates a fair value of €12.71 versus a price of €13.00 — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GAGV?
Our 21-model fair value for GAGV is €12.71 (as of Jun 26, 2026), built from audited fundamentals. The current price is €13.00.
What is the quality score of GAGV?
GAGV has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.